# An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

> **NCT03523338** · — · NO_LONGER_AVAILABLE · sponsor: **Aragon Pharmaceuticals, Inc.**

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Apalutamide
- **DRUG:** ADT (Standard of Care)

## Key facts

- **NCT ID:** NCT03523338
- **Lead sponsor:** Aragon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03523338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03523338, "An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03523338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*